<p><strong>经验丰富的生命科学领导者推动全球商业战略，加速早期和晚期生物制剂项目的增长</strong></p>
<p>, /PRNewswire/ -- 药明康德（Avid Bioservices, Inc.），一家专注于生物制剂合同开发和制造的组织（CDMO），今天宣布任命 Kerri McCullough Wood 为首席商业官。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Kerri McCullough Wood，药明康德首席商业官</p>
<p>McCullough Wood 是一位经验丰富的生物制药高管，拥有近三十年的 API、CDMO 和药品服务经验。她在加入药明康德之前，曾担任 Teva 旗下 TAPI 的首席商业官，负责一个跨越 15 个国家的全球组织，执行商业战略，加速增长计划，与全球制药公司建立强有力的合作关系，并提升整个业务的组织绩效。</p>
<p>在她的角色中，McCullough Wood 将领导药明康德的全球商业组织，包括业务发展、市场营销和战略合作伙伴关系。她将专注于加速产品管道的增长，加强客户关系，并进一步将药明康德的商业战略与其在早期开发到商业制造的扩展能力对齐。</p>
<p>&#34;Kerri 在公司重要的时刻加入药明康德，&#34;药明康德集团总裁兼首席执行官 Kenneth Bilenberg 表示。&#34;我们在早期阶段的卓越中心进行了重大投资，并扩大了我们的制造能力，以满足对美国本土生物制剂开发和制造日益增长的需求。Kerri 带来了强大的合作、运营卓越和项目执行的成功记录，这将帮助我们继续为我们服务的客户和患者提供支持。&#34;</p>
<p>McCullough Wood 的任命正值药明康德继续扩大其运营，以支持生物制药公司在整个开发生命周期中的需求，从早期项目到商业制造。该公司专注于速度、质量和运营可预测性，加上其美国本土的制造能力，使其能够满足行业对可靠和响应迅速的 CDMO 合作伙伴日益增长的需求。</p>
<p>&#34;我很高兴在药明康德如此关键的增长时刻加入，&#34;McCullough Wood 表示。&#34;公司在质量、灵活性和合作方面建立了良好的声誉。我期待与团队合作，扩大我们的商业覆盖面，加深客户关系，并帮助将更多疗法带给患者。&#34;</p>
<p>在 McCullough Wood 的领导下，药明康德将继续推进其使命，设定生物制剂制造的质量和合作标准，使能够提供改变患者生活的疗法。</p>
<p><strong>关于药明康德</strong></p>
<p>药明康德是一家全球合同开发和制造组织（CDMO），专注于哺乳动物细胞培养制造。总部位于美国，拥有无可挑剔的 FDA 记录，药明康德因其敏捷性、质量和应对复杂全球监管环境的能力而受到全球生物制药创新者的信任。药明康德拥有支持新兴生物科技和大型跨国制药公司的经验，提供从开发到商业供应的端到端解决方案。</p>
<p>药明康德的数字：</p>
<p>制造超过 600 批次</p>
<p>全球交付超过 275 批次商业产品</p>
<p>7 个以上获批的商业产品</p>
<p>在主要监管机构进行 10 次成功的预批准/预许可检查</p>
<p>来源：药明康德</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx"/></p>

CDMO

<p>Avid Bioservices, Inc. 任命 Kerri McCullough Wood 为首席商务官。她在生物制药领域拥有近 30 年的经验，将负责全球商业战略，专注于业务发展和加强客户关系。她的任命是在 Avid 扩大运营以满足对生物制剂开发和制造日益增长的需求之际。McCullough Wood 旨在提升 Avid 的商业覆盖范围，并支持将疗法交付给患者。Avid 是一家值得信赖的合同开发和制造组织（CDMO），以其在生物制药行业的质量和灵活性而闻名</p>

<p><strong>Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programs</strong></p>
<div class="lb-trans"><p><strong>经验丰富的生命科学领导者推动全球商业战略，加速早期和晚期生物制剂项目的增长</strong></p>
</div><p>, /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kerri McCullough Wood as Chief Commercial Officer.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 药明康德（Avid Bioservices, Inc.），一家专注于生物制剂合同开发和制造的组织（CDMO），今天宣布任命 Kerri McCullough Wood 为首席商业官。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Kerri McCullough Wood, Chief Commercial Officer, Avid Bioservices, Inc.</p>
<div class="lb-trans"><p>Kerri McCullough Wood，药明康德首席商业官</p>
</div><p>McCullough Wood is a seasoned biopharma executive with nearly three decades of experience across API, CDMO, and drug product services. She joins Avid following her role as Chief Commercial Officer at TAPI, a division of Teva, where she led a global organization spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong partnerships with global pharmaceutical companies, and enhancing organizational performance across the business.</p>
<div class="lb-trans"><p>McCullough Wood 是一位经验丰富的生物制药高管，拥有近三十年的 API、CDMO 和药品服务经验。她在加入药明康德之前，曾担任 Teva 旗下 TAPI 的首席商业官，负责一个跨越 15 个国家的全球组织，执行商业战略，加速增长计划，与全球制药公司建立强有力的合作关系，并提升整个业务的组织绩效。</p>
</div><p>In her role, McCullough Wood will lead Avid's global commercial organization, including business development, marketing, and strategic partnerships. She will focus on accelerating pipeline growth, strengthening client relationships, and further aligning Avid's commercial strategy with its expanding capabilities across early-phase development through commercial manufacturing.</p>
<div class="lb-trans"><p>在她的角色中，McCullough Wood 将领导药明康德的全球商业组织，包括业务发展、市场营销和战略合作伙伴关系。她将专注于加速产品管道的增长，加强客户关系，并进一步将药明康德的商业战略与其在早期开发到商业制造的扩展能力对齐。</p>
</div><p>&#34;Kerri joins Avid at an important time for the company,&#34; said Kenneth Bilenberg, Group President and Chief Executive Officer of Avid Bioservices. &#34;We've made significant investments in our early-phase Center of Excellence and expanded our manufacturing capabilities to meet growing demand for U.S.-based biologics development and manufacturing. Kerri brings a strong track record of partnership, operational excellence, and program execution that will help us continue delivering for the clients and patients we serve.&#34;</p>
<div class="lb-trans"><p>&#34;Kerri 在公司重要的时刻加入药明康德，&#34;药明康德集团总裁兼首席执行官 Kenneth Bilenberg 表示。&#34;我们在早期阶段的卓越中心进行了重大投资，并扩大了我们的制造能力，以满足对美国本土生物制剂开发和制造日益增长的需求。Kerri 带来了强大的合作、运营卓越和项目执行的成功记录，这将帮助我们继续为我们服务的客户和患者提供支持。&#34;</p>
</div><p>McCullough Wood's appointment comes as Avid continues to scale its operations to support biopharma companies across the full development lifecycle, from early-phase programs through commercial manufacturing. The company's focus on speed, quality, and operational predictability, combined with its U.S.-based manufacturing footprint, positions it to meet increasing industry demand for reliable and responsive CDMO partners.</p>
<div class="lb-trans"><p>McCullough Wood 的任命正值药明康德继续扩大其运营，以支持生物制药公司在整个开发生命周期中的需求，从早期项目到商业制造。该公司专注于速度、质量和运营可预测性，加上其美国本土的制造能力，使其能够满足行业对可靠和响应迅速的 CDMO 合作伙伴日益增长的需求。</p>
</div><p>&#34;I'm excited to join Avid at such a pivotal point in its growth,&#34; said McCullough Wood. &#34;The company has built a strong reputation for quality, flexibility, and partnership. I look forward to working with the team to expand our commercial reach, deepen client relationships, and help bring more therapies to patients.&#34;</p>
<div class="lb-trans"><p>&#34;我很高兴在药明康德如此关键的增长时刻加入，&#34;McCullough Wood 表示。&#34;公司在质量、灵活性和合作方面建立了良好的声誉。我期待与团队合作，扩大我们的商业覆盖面，加深客户关系，并帮助将更多疗法带给患者。&#34;</p>
</div><p>With McCullough Wood's leadership, Avid will continue advancing its mission to set the standard for quality and partnership in biologics manufacturing, enabling the delivery of therapies that transform patient lives.</p>
<div class="lb-trans"><p>在 McCullough Wood 的领导下，药明康德将继续推进其使命，设定生物制剂制造的质量和合作标准，使能够提供改变患者生活的疗法。</p>
</div><p><strong>About Avid</strong></p>
<div class="lb-trans"><p><strong>关于药明康德</strong></p>
</div><p>Avid Bioservices is a global contract development and manufacturing organization (CDMO) specializing in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators worldwide for its agility, quality, and ability to navigate complex global regulatory landscapes. With experience supporting both emerging biotech and large multinational pharma companies, Avid provides end-to-end solutions from development through commercial supply.</p>
<div class="lb-trans"><p>药明康德是一家全球合同开发和制造组织（CDMO），专注于哺乳动物细胞培养制造。总部位于美国，拥有无可挑剔的 FDA 记录，药明康德因其敏捷性、质量和应对复杂全球监管环境的能力而受到全球生物制药创新者的信任。药明康德拥有支持新兴生物科技和大型跨国制药公司的经验，提供从开发到商业供应的端到端解决方案。</p>
</div><p>Avid By the Numbers:</p>
<div class="lb-trans"><p>药明康德的数字：</p>
</div><p>More than 600 batches manufactured</p>
<div class="lb-trans"><p>制造超过 600 批次</p>
</div><p>Over 275 commercial batches delivered globally</p>
<div class="lb-trans"><p>全球交付超过 275 批次商业产品</p>
</div><p>7+ approved commercial products</p>
<div class="lb-trans"><p>7 个以上获批的商业产品</p>
</div><p>10 successful pre-approval/pre-license inspections across major regulatory agencies</p>
<div class="lb-trans"><p>在主要监管机构进行 10 次成功的预批准/预许可检查</p>
</div><p>SOURCE Avid Bioservices</p>
<div class="lb-trans"><p>来源：药明康德</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA56371&amp;Transmission_Id=202605111327PR_NEWS_USPR_____LA56371&amp;DateId=20260511"/></p>

Avid Bioservices 任命 Kerri McCullough Wood 为首席商务官